Screening for high blood pressure and preeclampsia in pregnant women
Studies a screening method to find pregnant women at risk of preeclampsia early.
Plain-language title generated from the registry record
Registry title: The Project of Gestational Hypertension and Preeclampsia Screening and Prevention Center
Key facts
- Where
- Guangzhou, ChinaSee the site
Where in China
- FANG HEGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Third Affiliated Hospital of Guangzhou Medical University
- Trial code
- NCT06383858
- Record updated
- 19 September 2024
- Original description
Preeclampsia is the main cause of illness and death in pregnant women and fetuses. Currently, there is no effective treatment for preeclampsia in clinical practice, and the fundamental treatment is still termination of pregnancy and placental delivery.Read full original descriptionShow less
The Project of Gestational Hypertension and Preeclampsia Screening and Prevention
Preeclampsia is the main cause of illness and death in pregnant women and fetuses. Currently, there is no effective treatment for preeclampsia in clinical practice, and the fundamental treatment is still termination of pregnancy and placental delivery.
Therefore, early prediction of preeclampsia and targeted strengthening of high-risk pregnant women supervision, early intervention and diagnosis and treatment can greatly reduce the serious obstetric complications and perinatal maternal and fetal deaths caused by preeclampsia, which has significant social and clinical significance.
Inclusion: 1) Pregnant women who have been screened for pre-eclampsia risk according to the clinical risk factors listed in NICE guidelines (2019); 2) Based on the authoritative guideline of Figo and the consensus of experts in China, pregnant women who routinely use maternal factor +MAP＋PLGF±UtA-PI in the first trimester or PLGF or sFlt-1/PLGF in the second and third trimesters to assess the risk of preeclampsia; 3) Meet any of the above conditions, join the group voluntarily, and sign the informed consent form.
Exclusion: 3) There are obvious other abnormal signs, laboratory tests or other clinical d• iseases, which are judged by the researcher to be not suitable for participating in researchers; 1) Severe fetal malformation or abnormality (no fetal heartbeat); 2) Those who regularly use aspirin before joining the group; 4) Unable to obtain follow-up and delivery information.